Mathematical modelling suggests that a system in which the products of one partner, like the glucagon produced by the pancreatic alpha cell, have a stimulatory effect on its counterpart, while the other partners products, like the insulin secreted by the beta cell, have inhibitory effects, enables active regulation to maintain stable levels, something that is indeed mandatory for the control of blood glucose concentration [1,2,3]
A complete medical history, including cardiovascular risk factors, thyroid disease, pancreatitis history, and current medications, is essential before considering GLP-1 agonist therapy
Fis1 acts as a mitochondrial recruitment factor for TBC1D15 that is involved in regulation of mitochondrial morphology
A short message to your prescriber often clears up questions quickly